van Berge Henegouwen, J. M.
van der Wijngaart, H.
Zeverijn, L. J.
Hoes, L. R.
Meertens, M.
Huitema, A. D. R.
Devriese, L. A.
Labots, M.
Verheul, H. M. W.
Voest, E. E.
Gelderblom, H. http://orcid.org/0000-0001-9270-8636
Clinical trials referenced in this document:
Documents that mention this clinical trial
Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine
https://doi.org/10.1136/esmoopen-2019-000516
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature
https://doi.org/10.1007/s00280-022-04437-z
Cutaneous lymphangitis carcinomatosa in salivary duct carcinoma
https://doi.org/10.1136/jcp-2022-208564
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).
https://doi.org/10.1200/jco.2024.42.16_suppl.3138
Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.
https://doi.org/10.1200/jco.2024.42.16_suppl.3116
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
https://doi.org/10.1200/jco.2023.41.16_suppl.3101
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
https://doi.org/10.1136/bmj-2023-079126
Funding for this research was provided by:
KWF Kankerbestrijding (10014)
Barcode for Life Foundation
The Hartwig Medical Foundation
Amgen Nederland
AstraZeneca
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Merck Sharp and Dohme
Clovis Oncology
Eisai
Janssen Pharmaceuticals
Lilly
Novartis
Pfizer Pharmaceuticals
Roche
Article History
Received: 11 January 2022
Accepted: 15 April 2022
First Online: 22 May 2022
Declarations
:
: All authors declare that they have no conflict of interest.
: This study was conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki’s ethical principles for medical research. Approval was granted by the Medical Ethical Committee of the Netherlands Cancer Institute in Amsterdam. Written informed consent was obtained from all study subjects.